RBMX Antibody

What is RBMX and what are its primary cellular functions?

RBMX (RNA Binding Motif Protein, X-Linked), also known as hnRNP G, is a nuclear protein primarily involved in RNA processing and regulation. It functions as an RNA-binding protein that plays critical roles in several cellular processes including alternative splicing of pre-mRNAs, maintenance of telomere stability, and regulation of gene expression. Recent research has demonstrated that RBMX directly binds to TERRA (telomeric repeat-containing RNA) and helps maintain telomere integrity . The protein is predominantly localized in the nucleus as confirmed by immunofluorescence assays, where it performs most of its regulatory functions . RBMX has also been identified as a potential tumor suppressor in bladder cancer, where it inhibits tumorigenicity and progression through regulation of alternative splicing mechanisms .

Which experimental applications are RBMX antibodies most suitable for?

RBMX antibodies are versatile tools applicable to multiple experimental techniques. Based on available data, these antibodies are particularly effective in:

Different antibodies targeting specific epitopes of RBMX offer varying degrees of reactivity across species. For instance, antibody ABIN6244062 targets amino acids 222-252 and reacts with human samples, while ABIN1533719 targets amino acids 6-55 and shows reactivity with human, rat, and mouse samples .

How should researchers select the appropriate RBMX antibody for their specific experimental needs?

Selecting the appropriate RBMX antibody requires considering multiple factors:

• Target epitope region: Different antibodies target distinct regions of RBMX (e.g., AA 6-55, AA 222-252, AA 262-294). The choice depends on which domain of the protein is relevant to your research question .

• Species reactivity: Some antibodies react only with human RBMX, while others detect the protein across multiple species. For example, ABIN6244062 is human-specific, whereas others show cross-reactivity with rat, mouse, and even zebrafish samples .

• Application compatibility: Certain antibodies are validated for specific applications. For instance, Cell Signaling's RBMX/hnRNP G (D7C2V) antibody is specifically validated for Western blotting and immunoprecipitation .

• Clonality consideration: Polyclonal antibodies offer broader epitope recognition but potentially lower specificity, while monoclonal antibodies (like D7C2V) provide greater specificity and lot-to-lot consistency .

• Purification method: Consider antibodies purified through protein A columns followed by peptide affinity purification for higher specificity in complex experiments .

For researchers studying specific RBMX interactions, such as those with TERRA or in telomeric R-loop formation, antibodies validated in related applications would be most appropriate .

What validation methods should be employed to confirm RBMX antibody specificity?

Rigorous validation is essential for ensuring reliable experimental results with RBMX antibodies:

• Knockout/knockdown controls: Compare antibody reactivity in RBMX-depleted cells (using siRNA knockdown or CRISPR knockout) with wild-type cells. Studies have successfully employed siRNA to silence RBMX expression, providing an excellent negative control for antibody specificity testing .

• Western blot analysis: Confirm the detection of a single band at the expected molecular weight (~42 kDa for RBMX) . Multiple or unexpected bands may indicate cross-reactivity with other proteins.

• Immunoprecipitation followed by mass spectrometry: This can verify that the antibody is capturing the intended target protein rather than related proteins.

• Recombinant protein testing: Use purified recombinant RBMX protein as a positive control to establish specific binding characteristics.

• Cross-species reactivity verification: If the antibody claims reactivity across multiple species, validate this experimentally, as sequence homology doesn't always translate to actual reactivity .

Research has demonstrated that properly validated RBMX antibodies can successfully detect endogenous RBMX in applications such as immunofluorescence assays to confirm nuclear localization .

How can RBMX antibodies be utilized to investigate the role of RBMX in telomere stability?

Recent research has established RBMX as a critical regulator of telomere stability through its interaction with TERRA (telomeric repeat-containing RNA). To investigate this relationship, researchers can employ several antibody-dependent methodologies:

• RNA-Protein Interaction Characterization: Researchers successfully used RBMX antibodies in RNA immunoprecipitation experiments to demonstrate direct binding between RBMX and TERRA. This involved incubating biotin-labeled RNA oligonucleotides containing UUAGGG repeats (synthetic TERRA) with nuclear extracts, recovering them using streptavidin-coated magnetic beads, and confirming RBMX binding through western blotting with RBMX antibodies .

• R-loop Detection Protocol: RBMX depletion increases telomeric R-loops, which can be detected using:

  • DNA-RNA immunoprecipitation (DRIP) with S9.6 antibody followed by hybridization with telomeric probes

  • Comparative analysis between control and RBMX-depleted cells showing increased signals after RBMX depletion

  • RNase H digestion sensitivity tests to confirm R-loop specificity

• Co-localization Analysis of Telomeric Factors: Combined immunofluorescence-in situ hybridization (IF-FISH) using RBMX antibodies, telomeric probes, and antibodies against DNA damage markers (γH2AX/53BP1) demonstrates that RBMX depletion leads to increased telomeric DNA damage .

These approaches have successfully established that RBMX depletion increases TERRA levels, promotes formation of telomeric R-loops, and ultimately leads to telomeric DNA damage, highlighting its crucial role in genome stability maintenance.

What methodologies can researchers employ to study RBMX's tumor suppressor function in cancer?

RBMX has been identified as a tumor suppressor in bladder cancer. To investigate this function, researchers can implement several methodologies using RBMX antibodies:

• Expression Analysis in Clinical Samples:

  • Immunohistochemistry comparing RBMX levels in non-muscle invasive bladder cancer (NMIBC), muscle invasive bladder cancer (MIBC), and normal tissue samples

  • Western blot quantification showing progressive downregulation of RBMX in cancer progression

  Tissue Type	Relative RBMX Expression	Statistical Significance
  Normal Tissue	High (reference)	-
  NMIBC	Reduced	Significant (p < 0.05)
  MIBC	Further reduced	Significant (p < 0.05)

• Functional Analysis Through Genetic Manipulation:

  • Establish stable overexpression or knockdown cell lines using lentiviral transduction

  • Validate expression changes by qRT-PCR and western blot with RBMX antibodies

  • Assess phenotypic changes through proliferation, colony formation, migration, and invasion assays

• Mechanistic Investigation of Alternative Splicing Regulation:

  • RNA immunoprecipitation with RBMX antibodies to identify direct RNA targets

  • Analysis of competitive binding between RBMX and hnRNP A1 to sequences flanking PKM exon 9

  • Quantification of PKM1/PKM2 isoform ratios after RBMX modulation

These approaches have revealed that RBMX inhibits BCa tumorigenicity and progression via an hnRNP A1-mediated PKM alternative splicing mechanism, shifting the balance from PKM2 to PKM1 and thereby attenuating aerobic glycolysis in cancer cells .

How can researchers optimize immunoprecipitation protocols with RBMX antibodies for protein-protein interaction studies?

Optimizing immunoprecipitation (IP) protocols with RBMX antibodies requires careful attention to several key parameters:

• Antibody Selection and Concentration:

  • Use antibodies specifically validated for IP applications, such as the RBMX/hnRNP G (D7C2V) Rabbit mAb

  • Start with recommended dilution of 1:50 for IP applications

  • For novel interactions, consider testing multiple antibody clones targeting different epitopes

• Cell Lysis and Nuclear Protein Extraction:

  • RBMX is predominantly nuclear, requiring efficient nuclear protein extraction

  • Use hypotonic buffers followed by nuclear lysis with high-salt buffers containing appropriate detergents

  • Include protease and phosphatase inhibitors to prevent protein degradation and modification changes

• Cross-linking Considerations:

  • For transient interactions, consider using reversible cross-linking reagents

  • Formaldehyde (0.1-1%) can be used for in vivo cross-linking prior to cell lysis

  • Include a de-cross-linking step before SDS-PAGE analysis

• RNase Treatment Evaluation:

  • Since RBMX is an RNA-binding protein, test parallel IPs with and without RNase treatment

  • This determines whether interactions are direct or RNA-mediated

  • For example, the RBMX-ZCCHC8 interaction study benefited from this approach

• Validation Controls:

  • Include IgG control from the same species as the RBMX antibody

  • Use RBMX-depleted cells as negative controls

  • Consider a reciprocal IP with antibodies against the suspected interacting protein

Recent research successfully used these approaches to demonstrate the interaction between RBMX and ZCCHC8, revealing their cooperative role in regulating TERRA and telomeric R-loop levels .

What are the key considerations when using RBMX antibodies to study alternative splicing mechanisms?

RBMX plays significant roles in alternative splicing regulation, particularly in the PKM gene splicing that impacts cancer metabolism. When investigating these processes with RBMX antibodies, researchers should consider:

• RNA-Protein Complex Immunoprecipitation:

  • Use RBMX antibodies for RNA immunoprecipitation (RIP) to identify direct RNA targets

  • Enhance specificity by using ultraviolet crosslinking followed by immunoprecipitation (CLIP)

  • Analyze bound RNAs by RT-PCR or high-throughput sequencing

• Competitive Binding Assays:

  • Develop in vitro binding assays to assess how RBMX competitively inhibits hnRNP A1 binding to PKM pre-mRNA

  • Use purified recombinant proteins and synthetic RNA oligos representing splicing regulatory elements

  • Quantify binding affinities under different conditions

• Splice Isoform Analysis:

  • Following RBMX overexpression or knockdown, analyze changes in splice isoform ratios

  • For PKM, specifically measure PKM1/PKM2, as RBMX shifts splicing toward PKM1

  • Use isoform-specific primers in qRT-PCR or RNA-seq with appropriate computational analysis

• Splicing Factor Colocalization Studies:

  • Perform dual immunofluorescence using RBMX antibodies alongside antibodies against other splicing factors

  • Analyze nuclear speckle localization patterns

  • Quantify changes in colocalization following transcriptional inhibition or stress

• Functional Readouts of Splicing Changes:

  • In the case of PKM splicing, measure glycolytic parameters following RBMX modulation

  • Connect splicing changes to downstream cellular phenotypes

  • For bladder cancer studies, this involved measuring cancer cell aggressiveness when RBMX levels were altered

These approaches have revealed that RBMX serves as a tumor suppressor by competitively inhibiting hnRNP A1's interaction with PKM pre-mRNA, thereby increasing PKM1 levels relative to PKM2 and attenuating the Warburg effect in cancer cells .

What challenges should researchers anticipate when using RBMX antibodies in R-loop detection and analysis?

R-loops, three-stranded nucleic acid structures consisting of an RNA-DNA hybrid and a displaced single-stranded DNA, represent a frontier in genomic stability research. RBMX has been implicated in regulating these structures at telomeres, but studying this relationship presents several challenges:

• R-loop Signal Specificity:

  • DRIP (DNA-RNA Immunoprecipitation) assays using S9.6 antibody can detect R-loops, but require RNase H controls to confirm specificity

  • After RBMX depletion, increased telomere precipitation by S9.6 must be verified as RNase H-sensitive to confirm true R-loop signals

• Distinguishing Direct vs. Indirect Effects:

  • Determine whether RBMX directly resolves R-loops or affects R-loop formation indirectly through:

    • Direct binding to R-loops using purified recombinant RBMX

    • Sequential ChIP experiments with RBMX antibodies followed by S9.6 antibody

    • Rescue experiments with RNase H1 overexpression in RBMX-depleted cells

• Detecting Site-Specific R-loops:

  • Telomeric R-loops require specialized detection methods:

    • DRIP followed by hybridization with telomeric probes

    • Quantitative PCR with telomere-specific primers

    • Microscopy-based visualization using antibodies against both RBMX and R-loops

• Quantifying R-loop Dynamics:

  • Develop pulse-chase experiments to measure R-loop turnover rates

  • Use inducible RBMX depletion systems to monitor temporal changes

  • Implement real-time visualization techniques with fluorescently tagged RBMX

Research has demonstrated that RBMX depletion leads to increased telomeric R-loops, resulting in genomic instability marked by elevated γH2AX/53BP1 foci at telomeres. Importantly, RNase H1 overexpression in RBMX-depleted cells reduces these DNA damage markers, confirming the R-loop dependency of the phenotype .

How can researchers address potential cross-reactivity issues with RBMX antibodies?

Cross-reactivity can significantly impact experimental reliability when working with RBMX antibodies. Researchers should implement several strategies to address this challenge:

• Antibody Selection Based on Epitope Uniqueness:

  • Choose antibodies targeting unique regions of RBMX that have limited homology with related proteins

  • Consider antibodies targeting the central region (AA 222-252) or N-terminal region (AA 6-55) depending on experimental needs

• Validation in Multiple Systems:

  • Test antibody specificity in multiple cell lines or tissue types

  • Include RBMX knockout/knockdown controls

  • Compare reactivity patterns across different antibody clones targeting distinct epitopes

• Peptide Competition Assays:

  • Pre-incubate the antibody with the immunizing peptide

  • True RBMX signals should be specifically blocked, while cross-reactive signals will persist

  • This is particularly useful for antibodies generated using synthetic peptide immunogens

• Immunodepletion Controls:

  • Perform sequential immunoprecipitations to deplete RBMX

  • Any signal remaining after complete RBMX depletion indicates cross-reactivity

  • This approach is especially valuable for applications like chromatin immunoprecipitation

• Species-Specific Considerations:

  • When working with non-human samples, select antibodies with validated cross-species reactivity

  • Consider sequence alignment between human RBMX and the target species' homolog

  • For example, some RBMX antibodies show reactivity across multiple species including human, rat, mouse, cow, and even zebrafish

These approaches help ensure that observed signals truly represent RBMX rather than related RNA-binding proteins with similar domains or structures.

What are the optimal storage and handling conditions for maintaining RBMX antibody quality?

Maintaining antibody quality throughout storage and experimental use is critical for consistent results. For RBMX antibodies, consider these guidelines:

• Storage Temperature and Aliquoting:

  • Store antibodies at -20°C for long-term storage

  • For frequently used antibodies, create small single-use aliquots to avoid freeze-thaw cycles

  • Working dilutions can be stored at 4°C for 1-2 weeks with preservatives

• Buffer Composition Considerations:

  • Most commercial RBMX antibodies are supplied in buffers containing:

    • Phosphate or Tris-buffered saline

    • Protein stabilizers (BSA, glycerol)

    • Preservatives (sodium azide)

  • Maintain these components when diluting antibodies

• Freeze-Thaw Management:

  • Limit freeze-thaw cycles to preserve antibody activity

  • Document number of freeze-thaw cycles for each aliquot

  • Consider using glycerol stocks (50% glycerol) for antibodies requiring multiple freeze-thaws

• Quality Control Monitoring:

  • Periodically test antibody performance using positive control samples

  • Compare signal intensity and specificity to reference standards

  • For recombinant antibodies like some newer RBMX antibodies, batch-to-batch consistency should be higher

• Transportation Considerations:

  • When transporting between laboratories, maintain cold chain

  • Use dry ice for shipping frozen antibodies

  • Document any temperature excursions during transportation

Following these guidelines will help maintain RBMX antibody performance, particularly important for quantitative applications like measuring RBMX expression differences between normal and cancer tissues .

How can RBMX antibodies be utilized in studying the role of RBMX in DNA damage response?

Recent research has implicated RBMX in DNA damage response pathways, particularly at telomeres. Researchers can leverage RBMX antibodies to investigate these processes through several approaches:

• DNA Damage Foci Co-localization Analysis:

  • Perform immunofluorescence combined with in situ hybridization (IF-FISH) using:

    • RBMX antibodies

    • Antibodies against DNA damage markers (γH2AX/53BP1)

    • Telomeric probe

  • This approach has revealed increased γH2AX/53BP1 foci at telomeres following RBMX depletion

• Recruitment Kinetics to Damage Sites:

  • Use laser microirradiation to induce localized DNA damage

  • Track RBMX recruitment using immunofluorescence with RBMX antibodies at various time points

  • Compare recruitment patterns with known DNA damage response factors

• Chromatin Fraction Analysis:

  • Following DNA damage induction, perform cellular fractionation

  • Use RBMX antibodies in western blotting to quantify RBMX levels in chromatin fractions

  • Compare normal conditions versus DNA damage-inducing treatments

• Interactome Changes After DNA Damage:

  • Conduct immunoprecipitation with RBMX antibodies before and after DNA damage

  • Identify differential interacting partners using mass spectrometry

  • Validate key interactions with reciprocal immunoprecipitation

• Post-translational Modification Analysis:

  • Use RBMX immunoprecipitation followed by mass spectrometry to identify damage-induced modifications

  • Develop modification-specific antibodies for key regulatory modifications

  • Map modification dynamics in response to different DNA damaging agents

Research has demonstrated that loss of RBMX leads to increased γH2AX expression levels and formation of 53BP1 foci at telomeres, indicating a protective role against telomeric DNA damage . These phenotypes are R-loop dependent, as they can be rescued by RNase H1 overexpression, suggesting RBMX functions in preventing R-loop-mediated genomic instability.

What potential exists for RBMX as a diagnostic or prognostic biomarker in cancer research?

RBMX has shown significant potential as a biomarker, particularly in bladder cancer. Researchers investigating this application should consider:

• Expression Analysis Across Cancer Types:

  • Use RBMX antibodies for tissue microarray immunohistochemistry across multiple cancer types

  • Correlate expression levels with clinical parameters and outcomes

  • In bladder cancer, RBMX downregulation correlates with disease progression and poorer prognosis

  Cancer Stage	RBMX Expression	Clinical Correlation
  Normal Tissue	High	Reference baseline
  NMIBC	Reduced	Better prognosis than MIBC
  MIBC	Further reduced	Poorer prognosis, increased progression

• Multivariate Analysis with Clinical Parameters:

  • Conduct comprehensive statistical analyses including:

    • Kaplan-Meier survival analysis based on RBMX expression levels

    • Cox regression models incorporating RBMX with other clinical factors

    • Receiver operating characteristic (ROC) curves to assess diagnostic performance

• Liquid Biopsy Development:

  • Explore detection of RBMX protein or RBMX-regulated splicing products in circulating tumor cells

  • Develop highly sensitive detection methods using RBMX antibodies

  • Correlate liquid biopsy findings with tissue expression and clinical outcomes

• Therapeutic Response Prediction:

  • Investigate whether RBMX expression levels predict response to specific therapies

  • Focus on treatments affecting pathways regulated by RBMX-mediated splicing

  • For bladder cancer, this might include metabolic-targeting therapies given RBMX's role in PKM splicing

• Combination Biomarker Panels:

  • Develop panels including RBMX alongside other markers

  • Use machine learning approaches to identify optimal marker combinations

  • Validate in independent patient cohorts

Analysis of The Cancer Genome Atlas (TCGA) cohort has confirmed that RBMX expression is significantly higher in tissues without regional lymph node metastasis compared to those with metastases (p = 0.0102), supporting its potential as a prognostic marker . These findings indicate that RBMX may serve as both a marker of BCa progression and a prognostic indicator for patients.

What are the most significant recent advances in RBMX antibody applications?

Recent research has significantly expanded our understanding of RBMX biology and the utility of RBMX antibodies in multiple research contexts. The most notable advances include:

• Telomere Stability Regulation: RBMX has been identified as a novel regulator of telomere integrity through direct binding to TERRA and regulation of telomeric R-loops. RBMX antibodies have been crucial in elucidating this function through RNA immunoprecipitation, DNA-RNA immunoprecipitation, and co-localization studies .

• Cancer Biology Applications: RBMX antibodies have revealed the protein's role as a tumor suppressor in bladder cancer, where it inhibits tumorigenicity and progression by regulating PKM alternative splicing. This has opened new avenues for biomarker development and potential therapeutic interventions .

• Alternative Splicing Mechanism Elucidation: Improved methodologies using RBMX antibodies have helped decipher how RBMX competitively inhibits hnRNP A1 binding to modulate alternative splicing of cancer-relevant genes like PKM, shifting the balance from PKM2 to PKM1 and thereby affecting cancer metabolism .

• R-loop Biology Insights: RBMX antibodies have been instrumental in connecting RBMX function to R-loop regulation at telomeres, with RBMX depletion leading to increased telomeric R-loops and subsequent DNA damage. This establishes RBMX as an important factor in genomic stability maintenance .

• Recombinant Antibody Development: The production of recombinant RBMX antibodies has improved consistency and reproducibility in research applications, providing superior lot-to-lot consistency and continuous supply without animal-derived components .

These advances collectively establish RBMX antibodies as valuable tools for investigating fundamental cellular processes and disease mechanisms, particularly in cancer biology and genome stability research.

What methodological improvements are needed to enhance RBMX antibody applications in future research?

Despite significant progress, several methodological improvements would further enhance RBMX antibody applications:

• Development of Modification-Specific Antibodies:

  • Generate antibodies specifically recognizing post-translationally modified forms of RBMX

  • Focus on phosphorylation, methylation, and SUMOylation sites that may regulate RBMX function

  • These would enable monitoring of RBMX regulatory dynamics in response to cellular stimuli

• High-Throughput Compatible Formats:

  • Develop RBMX antibody-based assays compatible with high-throughput screening

  • Create automated immunofluorescence workflows for studying RBMX localization changes

  • Implement multiplexed detection systems for simultaneous analysis of RBMX with interacting partners

• Single-Cell Analysis Adaptations:

  • Optimize RBMX antibodies for single-cell protein analysis techniques

  • Develop protocols for mass cytometry (CyTOF) inclusion of RBMX

  • Create imaging mass cytometry applications for spatial RBMX analysis in tissue contexts

• Live-Cell Imaging Compatible Approaches:

  • Develop cell-permeable RBMX antibody fragments or alternative binding proteins

  • Create techniques for monitoring RBMX dynamics in living cells

  • Implement CRISPR-based endogenous tagging strategies compatible with existing antibodies

• Improved Cross-Species Validation:

  • Systematically validate RBMX antibodies across multiple model organisms

  • Develop specific validation datasets for each species

  • Create resources documenting epitope conservation across evolutionary distances